Scarica l'app Stockscreener
4.71
0.43%
0.02
Dopo l'orario di chiusura:
4.72
0.010
+0.21%
Precedente Chiudi:
$4.69
Aprire:
$4.51
Volume 24 ore:
78,729
Relative Volume:
0.17
Capitalizzazione di mercato:
$49.37M
Reddito:
$52.29M
Utile/perdita netta:
$-73.52M
Rapporto P/E:
-7.1364
EPS:
-0.66
Flusso di cassa netto:
$-100.45M
1 W Prestazione:
+3.74%
1M Prestazione:
-5.80%
6M Prestazione:
-50.58%
1 anno Prestazione:
-69.49%
Intervallo 1D:
$4.51
$4.79
Intervallo di 1 settimana:
$4.25
$4.99
Portata 52W:
$3.61
$15.33
Precision Biosciences Inc Stock (DTIL) Company Profile
Nome
Precision Biosciences Inc
Settore
Industria
Telefono
919-314-5512
Indirizzo
302 EAST PETTIGREW STREET, DURHAM, NC
Confronta DTIL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
4.71 | 49.37M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | Iniziato | Guggenheim | Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-06-09 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | Ripresa | BTIG Research | Buy |
| 2020-04-03 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-05 | Iniziato | Stifel | Buy |
| 2020-02-25 | Iniziato | William Blair | Outperform |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-22 | Iniziato | Barclays | Overweight |
| 2019-04-22 | Iniziato | Goldman | Buy |
| 2019-04-22 | Iniziato | JP Morgan | Overweight |
| 2019-04-22 | Iniziato | Jefferies | Buy |
Mostra tutto
Precision Biosciences Inc Borsa (DTIL) Ultime notizie
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - BioSpace
Gene Editing Pioneer Precision BioSciences Reveals Latest ARCUS Platform Progress at Major Healthcare Conference - Stock Titan
Precision Biosciences director Kevin Buehler buys $21,122 in stock By Investing.com - Investing.com Australia
Precision Biosciences director Melinda Brown buys $8,735 in stock By Investing.com - Investing.com South Africa
Precision Biosciences director Kevin Buehler buys $21,122 in stock - Investing.com India
Precision Biosciences director Melinda Brown buys $8,735 in stock - Investing.com India
Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates - MSN
Precision Biosciences director Germano Geno J purchases $17,225 in stock By Investing.com - Investing.com South Africa
Precision Biosciences director Germano Geno J purchases $17,225 in stock - Investing.com India
Precision BioSciences: Q4 Earnings Snapshot - Big Rapids Pioneer
Precision BioSciences Reports Positive 2024 Financial Results - TipRanks
Precision BioSciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PRECISION BIOSCIENCES Earnings Results: $DTIL Reports Quarterly Earnings - Nasdaq
Precision Biosciences Reports Fourth Quarter And FY 2024 Results - MarketScreener
Precision BioSciences Inc Q4 Sales Decline - Nasdaq
Breakthrough: Precision BioSciences' Gene Editing Therapy Delivers First Results in HBV Patients - Stock Titan
Precision Biosciences CEO sells $5,359 in stock By Investing.com - Investing.com Australia
Precision Biosciences CEO sells $5,359 in stock - Investing.com India
Character Biosciences Raises $93 Million Series B to Advance Precision Medicine for Progressive Eye Diseases - Business Wire
PRECISION BIOSCIENCES Earnings Preview: Recent $DTIL Insider Trading, Hedge Fund Activity, and More - Nasdaq
Gene Editing Tools Market Growth Demand, Segment Analysis - openPR.com
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025 - BioSpace
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025 - Business Wire
Precision BioSciences Earnings Call: Key ARCUS Gene Editing Platform Updates Expected March 26 - StockTitan
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
H.C. Wainwright maintains $60 target on Precision BioSciences stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $60 target on Precision BioSciences stock - Investing.com
Revolutionary Gene Therapy Achieves 99% Hepatitis B Virus EliminationKey Trial Updates - Stock Titan
Precision Bio rises after gene editing data: BMO upgrades (update) - MSN
Assessing Precision BioSciences: Insights From 4 Financial Analysts - Benzinga
FDA Clears First-Ever In Vivo Gene-Editing Trial for Chronic Hepatitis B in the United States - CRISPR Medicine News
Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - 01Net
Revolutionary DMD Treatment Restores 93% Muscle Strength, Could Help 60% of Patients - StockTitan
Precision BioSciences' IND Application For PBGENE-HBV Gets FDA Clearance; Stock Climbs - RTTNews
Precision Says its Investigational New Drug Application for Hepatitis B Treatment Gets US FDA's Clearance - MarketScreener
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - NewsBreak: Local News & Alerts
Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B - BioSpace
Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL) - Seeking Alpha
(DTIL) Trading Advice - Stock Traders Daily
Precision Biosciences Inc Azioni (DTIL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):